Company Overview and News

 
China stocks flat at midday; Hong Kong gains 0.2%

2018-08-28 thehindubusinessline
Chinese stocks took a breather on Tuesday morning and were flat after strong gains on Monday, as the central bank took steps to stabilise the yuan, and as the news of US and Mexico agreeing to overhaul a trade pact brought relief to the region.
WWNTF 532617 SZHIF 0151 JETAIRWAYS 1088 0384 1099 2313 CGHLY WWNTY 2007 0914 CGHOF

5
Explore China's Booming Biopharma Space With This New ETF

2018-08-16 zacks
Loncar Investments along with Exchange Traded Concepts has come up with a marvel ETF targeting China’s booming biotech industry — Loncar China BioPharma Index ETF .
HD OXY 2196 WXXWY 1099

4
Deals of the day-Mergers and acquisitions

2018-07-12 reuters
July 12 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1300 GMT on Thursday:
FOX CCV CMCSA CCZ CAIAF SANT CA BKI 1099 BNC BPESY CCV.CL BOE WFT AVGO BPESF EGL BRCM BA FOXA CMCSK SAN

4
Deals of the day-Mergers and acquisitions

2018-07-12 reuters
July 12 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Thursday:
FOX CCV CMCSA CCZ CAIAF SANT CA 1099 BNC CCV.CL BOE BPESY WFT AVGO BPESF EGL BRCM BA FOXA CMCSK SAN

 
HK stocks fall ahead of next week's Trump-Kim summit, Fed meeting

2018-06-08 theedgemarkets
SHANGHAI (June 8): Hong Kong stocks fell the most in two weeks on Friday, as investors braced for a series of market-moving events next week including the US-North Korea summit and the Federal Reserve's policy meeting.
SWRAY CRWOY SWRBY 0390 CGHLY CRWOF SWRBF SWRAF CGHOF 0384 1099

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...